Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01209689
Other study ID # WA22908
Secondary ID 2009-017488-40
Status Terminated
Phase Phase 3
First received September 24, 2010
Last updated December 11, 2012
Start date October 2010
Est. completion date December 2011

Study information

Verified date December 2012
Source Hoffmann-La Roche
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This randomized, double-blind, placebo-controlled study evaluated the safety and efficacy of tocilizumab (RoActemra/Actemra) in patients with ankylosing spondylitis (AS) who had an inadequate response to previous tumor necrosis factor (TNF) antagonist therapy. Patients were randomized to receive tocilizumab at a dose of either 8 mg/kg or 4 mg/kg intravenously (iv) or placebo every 4 weeks for 24 weeks. The double-blind treatment period was followed by open-label treatment with tocilizumab 8 mg/kg iv every 4 weeks until Week 104 for all patients.

This study and all further clinical development of tocilizumab AS was halted after a review of 12-week data from Study NA22823, a randomized double-blind, placebo-controlled study in TNF antagonist naïve AS patients, failed to demonstrate efficacy.


Recruitment information / eligibility

Status Terminated
Enrollment 113
Est. completion date December 2011
Est. primary completion date December 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adult patients = 18 years of age.

- Ankylosing spondylitis as defined by the modified New York criteria for = 3 months prior to baseline.

- Active disease at screening and baseline (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] = 4.0, spinal pain visual analog scale [VAS] = 40).

- Inadequate response or intolerant to 1 or more previous non-steroidal anti-inflammatory drugs (NSAIDs).

- Inadequate response to treatment with etanercept, infliximab, adalimumab, or golimumab because of inadequate efficacy.

- Tumor necrosis factor (TNF) antagonist therapy must have been discontinued at least 8 weeks prior to baseline (etanercept 4 weeks).

- Traditional disease-modifying anti-rheumatic drugs (DMARDs) must be withdrawn for at least 4 weeks prior to baseline (methotrexate, sulfasalazine, and hydroxychloroquine or chloroquine may be allowed if at stable dose for at least 4 weeks prior to baseline).

- Oral corticosteroids (= 10 mg/day prednisone or equivalent) and NSAIDs/cyclooxygenase-2 [COX-2] inhibitors must be at stable dose for at least 4 weeks prior to baseline.

Exclusion Criteria:

- Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after randomization.

- Total ankylosis of spine (as determined by investigator).

- Inflammatory rheumatic disease other than ankylosing spondylitis.

- Active, acute uveitis at baseline.

- Previous treatment with tocilizumab.

- Intra-articular or tendon injections or parenteral corticosteroids within 4 weeks prior to screening.

- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies.

- Active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infection.

- History of or currently active primary or secondary immunodeficiency.

- Body weight > 150 kg.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Tocilizumab

Placebo


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Hoffmann-La Roche

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  Brazil,  Bulgaria,  Canada,  Czech Republic,  Denmark,  France,  Germany,  India,  Italy,  Lithuania,  Netherlands,  Poland,  Slovakia,  South Africa,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of ASsessment in Ankylosing Spondylitis 20 (ASAS20) Responders at Week 12 ASAS20 was defined as an improvement of = 20% and an absolute improvement of = 10 units on a 0-100 visual analog scale (VAS) from Baseline to Week 12 in 3 of 4 domains: 1-Patient global assessment (with extremes labelled none and severe), 2-Pain assessment (average total and nocturnal pain scores with extremes labelled no pain and most severe pain), 3-Function (represented by the Bath Ankylosing Spondylitis (BAS) Functional Index [BASFI] average of 10 questions regarding ability to perform specific tasks with extremes labelled easy and impossible), and 4-Inflammation (average of the last 2 questions on the 6-question BAS Disease Activity Index [BASDAI] concerning morning stiffness intensity with extremes labelled none and very severe and duration between 0 and 2 or more hours); and the absence of deterioration (of at least 20% and absolute change of at least 10 units on a 0-100 mm scale) in the remaining domain. Baseline to Week 12 No
See also
  Status Clinical Trial Phase
Completed NCT01208207 - A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108) Phase 3
Completed NCT02509026 - Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA Phase 4
Completed NCT02704845 - Biopsychosocial Exploration of Pain Profiles in Inflammatory and Chronic Non-specific Axial Low Back Pain N/A
Terminated NCT01209702 - A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs Phase 3
Terminated NCT00766402 - An Efficacy and Safety Study of Tramadol/Acetaminophen Versus Diclofenac in the Treatment of Pain in Participants With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs) Phase 4
Completed NCT00000433 - Blocking Tumor Necrosis Factor in Ankylosing Spondylitis Phase 2
Completed NCT00779935 - Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED) Phase 4
Completed NCT00779012 - A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED) Phase 4
Completed NCT01863732 - Extension in AS: Sustainability of Benefits, Safety and Tolerability Phase 3
Recruiting NCT05879419 - Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Phase 4
Completed NCT01567878 - Ultrasound of Enthesis in Patients With Ankylosing Spondylitis: a Comparative Study With Health Subjects N/A
Completed NCT01188655 - Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis N/A
Completed NCT00760669 - An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants Phase 4
Completed NCT02159053 - 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis Phase 3
Completed NCT00202865 - Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352) Phase 3
Completed NCT02374502 - Increasing Physical Activity in Ankylosing Spondylitis: a Randomised Controlled Trial N/A
Withdrawn NCT00298012 - Methotrexate in the Treatment of Axial Spondyloarthritis Phase 4
Terminated NCT00273858 - Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis N/A
Completed NCT04810715 - Frequency of Pes Planus and Posterior Tibial Tendon Dysfunction in Patients With Ankylosing Spondylitis
Completed NCT03880968 - Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis